<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Virtue Therapeutics</title>
    <link>https://akshayvtx.github.io/</link>
    <description>Recent content on Virtue Therapeutics</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language><atom:link href="https://akshayvtx.github.io/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>About</title>
      <link>https://akshayvtx.github.io/about/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://akshayvtx.github.io/about/</guid>
      <description>Agonism by Design Pioneering the Future of GPCR Drug Discovery At Virtue Therapeutics, we are at the forefront of revolutionizing the field of computational drug discovery, with a specialized focus on the challenging yet promising G Protein-Coupled Receptors (GPCRs). As the largest human protein family, GPCRs play a pivotal role in numerous diseases, including diabetes, obesity, depression, and sexual dysfunction. About 1/3rd of all approved drugs target GPCRs, highlighting their significance in therapeutics developments.</description>
    </item>
    
  </channel>
</rss>
